People with type-1 and type-2 diabetes have to monitor blood glucose and concern themselves with insulin injections.
Inhalable insulin may be easier on diabetics. It's easier to administer outside of the home and peaks in a shorter amount of time. This type of delivery system has minor side effects in the lungs, so those with lung issues may not be suitable candidates for inhalable insulin.
Endocrinologist Dr. Jean Luis Selam joins Melanie Cole, MS, to discuss inhalable insulin.
Inhalable Insulin: Viable Option for Diabetics
Inhalable insulin may be a good alternative to injections.
Additional Info
- Segment Number: 4
- Audio File: health_radio/1622ml5d.mp3
- Featured Speaker: Jean Louis Selam, MD
- Guest Website: Diabetes Research Center
- Guest Facebook Account: www.facebook.com/Afrezza
- Guest Twitter Account: @Afrezza
-
Guest Bio:
Dr. Jean Louis Selam received his undergraduate education and medical doctorate in France, University of Montpellier. He is a specialist in internal medicine and endocrinology in France since 1979 and is licensed in California since 1987. He has worked as an associate professor at University of California Irvine Diabetes Research Program 1986-90 then as an associate professor at University Medical School of Paris, department of Diabetology 1990-2003. He has been appointed in 2005 as Visiting Professor by the USC School of Medicine, Los Angeles.
Dr. Selam joined the Diabetes Research Center in Tustin, California (dba University Clinical Investigators Inc.) in 2003 which he became CEO in 2006. The Diabetes Research Center has performed over 200 phase 1-4 diabetic studies, the majority in the fields of insulin, oral medications, neuropathy and obesity. Dr Selam is the author of 116 peer-reviewed publications, 128 invited articles or chapters in books, and 354 conference presentations, the majority in the field of new techniques of insulin therapy including intensive insulin and implantable insulin pumps, which he is considered as a world leader. He also has performed pioneer work on intraperitoneal insulin and insulin-induced remissions. He is the Editor in Chief of the Journals Infusystems, which he founded in 1983, a world leading journal in the field of insulin delivery systems. Dr Selam has maintained direct clinical responsibility of diabetic patients in France as well as in his current position in the U.S. - Length (mins): 10
- Waiver Received: No
- Host: Melanie Cole, MS
Published in
Health Radio